A novel drug combination of a proteasome inhibitor, bortezomib and a histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA) was tested in nasopharyngeal carcinoma (NPC) both in vitro and in vivo. Dose-response of different concentrations of bortezomib and SAHA on inhibition of cell proliferation of NPC was determined. Mechanisms of apoptosis and effects on lytic cycle activation of 
Introduction:
Nasopharyngeal carcinoma (NPC) is concentrated in Southern Chinese populations in Southeast Asia, North Africans, Greenlanders and Alaskan Eskimos but is rare in other populations of the world. It has a predilection to affect young adult males. The incidence rate reaches ~25 per 100,000 males in Southern Chinese (1) . The disease has uniquely strong association with Epstein-Barr virus (EBV) when compared with other head and neck malignancies (2) . Radiotherapy is the mainstay of NPC treatment and confers cytotoxicity through generation of reactive oxygen species (ROS) (3).
Chemotherapy is required in locally advanced or metastatic cases and commonly used chemotherapeutic drugs include cisplatin and docetaxel (4) . Although NPC is both radiosensitive and chemosensitive, the standard treatment regimen results in significant long term sequelae. Moreover, the disease relapse rate is relatively high with poor survival chance for recurrent or metastatic disease (5) . Development of novel therapeutic strategies against the disease is clearly needed.
Proteasome and histone deacetylase inhibitors are two classes of promising therapeutic agents for cancer treatment. Bortezomib is a proteasome inhibitor approved by FDA for the treatment of multiple myeloma and relapsed mantle cell lymphoma (6) . Its cytotoxicity is associated with the downstream effects of proteasome inhibition including cyclin destabilisation, accumulation of tumor suppressor p53 and inactivation of nuclear factor-țB (NF-țB) (7, 8) . Suberoylanilide hydroxamic acid (SAHA; also known as vorinostat) is a histone deacetylase inhibitor approved by FDA for the treatment of cutaneous T-cell lymphoma. It alters gene expression by histone acetylation and mediates various cellular effects, including cell differentiation, cell cycle arrest and apoptosis, in different cancer cell types (9) (10) (11) (12) . Combination of bortezomib and SAHA (bortezomib/SAHA) was shown to be effective in the treatment of hematologic malignant cells such as multiple myeloma (13) , mantle cell lymphoma (14) , cutaneous T-cell lymphoma (15) and leukemia (16, 17) . Bortezomib/SAHA triggers apoptosis through caspase activation (14, (16) (17) (18) and ROS generation (13) (14) (15) (16) 19) in various types of cancers. Other cellular effects of combined proteasome and histone deacetylase inhibitors in various cancer types include histone acetylation (20, 21), aggresome disruption (22), NF-țB inactivation (13, 14, 16, 17, 19) , p53 and p21 up-regulation (13, 15, 16, 18) , c-Jun NH2-terminal kinase activation (13, 17) and mitochondrial membrane dysfunction (13, (16) (17) (18) .
Proteasome and histone deacetylase inhibitors were also reported to induce EBV lytic cycle in different EBV-associated malignancies and lead to specific therapeutic effects against the cancer cells (11, 12, 23, 24) . Bortezomib was reported to induce EBV lytic cycle in EBV-positive Burkitt lymphoma and gastric carcinoma cells (25) .
Induction of EBV lytic cycle by bortezomib could activate the radioisotope [ 125 I]2'-fluoro-2'-deoxy-β-D-5-iodouracil-arabinofuranoside to selectively suppress the growth of Burkitt lymphoma xenografts in SCID mice (25) . Our laboratory has previously shown that SAHA could significantly induce viral lytic cycle in EBV-positive gastric carcinoma and NPC cells and mediate enhanced apoptosis (11, 12) . The lytic cycle induction and tumor growth suppression mediated by SAHA could also be observed in NPC xenografts established in nude mice (12) .
Since bortezomib and SAHA have synergistic action on various malignant cell types and both drugs can induce viral lytic cycle in EBV-associated malignancies, we set out to investigate the effects of combining bortezomib and SAHA in the treatment of (12) . NP460 is a normal nasopharyngeal epithelial cell line immortalized with human telomerase reverse transcriptase gene (26) . Human kidney 2 (HK2) is a normal kidney cell line immortalized with human papillomavirus 16 E6/E7 genes (Gift from Prof. G.C.F. Chan, The University of Hong Kong) (27) . All the cell lines were cultured as previously described (12, 26, 27) . In The STR profiles were compared with DSMZ database. Cells were tested on August 2011. 
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Western blot analysis
HA and C666-1 cells were treated with drugs for 24 hr and 48 hr, respectively.
Protein from the cell cultures was extracted and western blot analysis was performed as described previously (11) . EBV proteins and apoptotic proteins were detected with the antibodies reported previously (12) . Cleavage of caspase-8 was detected with Tumors were dissected and weighed after euthanasia, followed by extraction of protein for western blot analysis. 
Statistical analysis
In vitro experiments were performed in triplicate and repeated at least 3 times. Data were analyzed for statistical significance using unpaired Student t test. P value < 0.05 was considered statistically significant. To evaluate the synergism of bortezomib and SAHA, isobolograms were generated from inhibitory concentrations plotted as a function of the concentration of bortezomib versus the concentration of SAHA. Here, the IC60 curves were plotted on the isobolograms and were compared with the additive isoboles comparing the two IC60s of each drug. Curves that lie under the additive isobole suggest synergism and vice versa (29) . The combination index (CI) was calculated using the Chou and Talalay method using Microsoft Excel software (30) . CI<1, =1 and >1 represents synergy, additivity and antagonism, respectively. All statistical analyses were determined using GraphPad Prism Version 5.0 software. (Fig. 2b) . Upon treatment with bortezomib/SAHA, increased number of NPC cells expressing cleaved PARP and cleaved caspase-3 were also detected by immunofluoresent staining (Fig. 2c) . The apoptosis was caspase-dependent because a pan-caspase inhibitor, Z-VAD-FMK, significantly suppressed the cleavage of PARP and caspase-3, -7 and -9 induced by bortezomib/SAHA (Fig. 2d) .
Bortezomib/SAHA's cytotoxic effect was strongly associated with reactive oxygen species (ROS)
Bortezomib/SAHA induced ROS generation in a wide variety of cancer cell lines (13) (14) (15) (16) 19) . We, therefore, hypothesized that ROS generation were also involved in bortezomib/SAHA-induced apoptosis in NPC cells. DCFH-DA assay demonstrated enhanced ROS content in HA and C666-1 cells treated with bortezomib/SAHA at 24 hr and 48 hr post-treatment, respectively. N-acetyl cysteine (NAC), a ROS scavenger, significantly reduced the generation of ROS (Fig. 3a) . NAC also effectively 
suppressed apoptosis, as indicated by the reduction of TUNEL-positive and sub-G1 populations in NPC cells upon treatment with bortezomib/SAHA. The TUNEL-positive NPC cells dropped from 52.4% to 1.74% for HA and from 57.8% to 41.9% for C666-1 (Fig. 3b) . The corresponding sub-G1 population dropped from 38.9% to 6.9% for HA and from 40.7% to 17.9% for C666-1 (Fig. 3c) . We also examined other possible mechanisms of cell death that would be induced by bortezomib/SAHA. While SAHA mildly induced acetylation of histone H3 and H4, addition of bortezomib resulted in a more significant increase in histone acetylation (Fig. 3d) . Meanwhile, the histone acetylation induced by bortezomib/SAHA reduced upon co-incubation with either Z-VAD-FMK or NAC, indicating that the histone acetylation was caspase-and ROS-dependent ( Fig. 3d and Fig. S2 ). Specific caspase-8 inhibitor Z-IETD-FMK, but not caspase-9 inhibitor Z-LEHD-FMK, completely reduced the level of acetylated histone and partially reduced the cleavage of PARP, showing that bortezomib/SAHA-induced cell death was partially related to caspase-8-dependent histone acetylation (Fig. 3e) . NK-κB activation and mitochondrial membrane potential were shown to be closely associated with ROS generation (31, 32) . However, according to our results, no significant change in expression of NF-κB-related proteins, including p-p65, p65 and IKK-α/β, was observed after treatment with combined bortezomib/SAHA when compared with either drug alone (Fig. 3d) . The drug combination also did not result in significant loss of mitochondrial membrane potential in the bortezomib/SAHA-treated cells (Fig. 3f) .
Caspase activation were regulated by ROS signaling in NPC cells
To further investigate the roles of caspases and ROS in NPC apoptosis, we analyzed the effects of NAC and Z-VAD-FMK on caspase activation and ROS generation 
mediated by bortezomib/SAHA. NAC effectively suppressed the cleavage of PARP and caspase-3, -7 and -9 in both HA and C666-1 cells (Fig. 4a) . Moreover, NAC significantly decreased the percentage of cells containing active caspase-3/-7 following treatment with bortezomib/SAHA (Fig. 4b) . The percentages decreased from 39.3% to 5.75% in HA cells and from 58% to 10.5% in C666-1 cells. On the other hand, Z-VAD-FMK, which effectively suppressed caspase activation, did not reduce ROS generation induced by bortezomib/SAHA (Fig. 2d & 4c) . These suggest ROS induction by bortezomib/SAHA led to subsequent caspase activation in NPC cells.
Bortezomib inhibited SAHA's induction of EBV lytic protein expression and abrogated production of infectious viral particles in NPC cells
Induction of EBV lytic cycle could lead to apoptosis of EBV-positive NPC cells (12).
We, therefore, investigated the expression of EBV immediate-early lytic (Zta) and latent (EBNA1) proteins in HA and C666-1 cells after treatment with bortezomib/SAHA for 24 hr and 48 hr, respectively. As expected, SAHA significantly induced Zta expression in HA cells but not in C666-1 cells (in which Zta could only be detected after treatment with SAHA for 3 days) (12) at these time points (Fig. 5a &   b) . Addition of bortezomib effectively reduced the expression of SAHA-induced Zta in HA cells (Fig. 5a & b) . Time course experiment showed that bortezomib/SAHA induced proteolytic cleavage of PARP and caspase-9 at an earlier time point (12 hr post-treatment) when compared with either drug alone (24 hr post-treatment) (Fig. 5c ).
Apoptosis was triggered at 12 hr post-treatment while expression of Zta was observed later at ~24 hr post-treatment (Fig. 5c) EBV late lytic protein, gp350/220, was totally abrogated after treatment with bortezomib/SAHA when compared with SAHA alone (Fig. 5c ). Bortezomib could also abrogate SAHA-induced EBV DNA replication and infectious virus production.
At 48 hr post-treatment, the viral load was 1258 genomes per cell in HA treated with SAHA and it dropped to 172 genomes per cell when HA was co-incubated with bortezomib (Fig. 5d) . The effect cannot be observed in C666-1 as SAHA was not capable of activating EBV DNA replication in C666-1 as reported previously (data not shown) (12) . Supernatants from HONE1-EBV treated with SAHA could effectively infect ~29% Daudi cells with EBV. However, when bortezomib was added, only ~3% Daudi cells were infected with EBV (Fig. 5e) . Moreover, the synergistic killing by bortezomib/SAHA could be observed similarly in both EBV-negative and EBV-positive NPC cells (Fig. S3) . These data suggest that the synergism of bortezomib/SAHA on apoptosis of NPC cells was independent of the presence of EBV. 28, the tumor mass of C666-1 in the control group increased to 1000 mg. The mass of tumors treated with bortezomib and SAHA increased to 760 mg and 580 mg respectively, while that treated with drug combination gave a much smaller increase in tumor mass to 270 mg (Fig. 6b) . Western blot analysis showed that bortezomib/SAHA could induce a stronger proteolytic cleavage of PARP and caspases in the tumors when compared with either drug alone (Fig. 6c) . Similar anti-tumor effects of bortezomib/SAHA could also be observed in HONE1 and HA xenografts ( Fig. 6d and S4 ). The weight of mice was recorded throughout the experiments.
Weight loss of ~5% was observed in mice treated with either the single drugs or their combination (Fig. S4) . No significant increase in weight loss was observed in the mice treated with the combined drug regimen. Based on the observations in all three mouse tumor models (C666-1, HONE1 and HA), the toxicity (generally mild) seems to be similar for either the single drugs or their combination. 
Discussion
We demonstrated that combination of bortezomib and SAHA could synergistically inhibit proliferation of all four EBV-positive NPC cell lines employed in this study.
The synergistic killing was specific to NPC when compared with normal nasopharyngeal and kidney cells and was mediated by increased apoptosis. We showed that bortezomib/SAHA could significantly induce activation of caspase-3, -7 and -9 while addition of caspase inhibitor, Z-VAD-FMK, could effectively reduce the cleavage of the caspases and PARP, suggesting a caspase-dependent apoptosis of the NPC cells. We also observed a significant increase in ROS generation in NPC cells reduce the acetylation of the histones. The results were similar to the induction of caspase-8-dependent histone acetylation by combination of HDAC and proteasome inhibitors in leukemic cells (21). One of the major effects mediated by histone hyperacetylation is up-regulation of tumor suppressor genes (9) . However, we did not find any up-regulation of Rb or p53 in the bortezomib/SAHA-treated NPC cells (refer to Fig. S2a ). p53 expression was repressed by the combination treatment in HA cells whereas such repression was not found in C666-1 cells. Since enhanced apoptosis was observed in both HA and C666-1 cells, the cell death was unlikely related to the p53 pathway. It is unexpected that NF-κB inactivation, which was seen in vitro in various cancer cell lines after treatment with bortezomib/SAHA, was not observed in the NPC cells. However, this finding is in line with that in a clinical study on patients with multiple myeloma where the clinical response to bortezomib/SAHA did not correlate to the expression pattern of NF-κB p65 subunit protein in the bone marrow (35) . Loss of mitochondrial membrane potential was not significantly detected in the bortezomib/SAHA-treated NPC cells, which was consistent with the finding that caspase-9 specific inhibitor, Z-LEHD-FMK, could not suppress the apoptosis of NPC cells. We postulated that the apoptosis was not mediated through the intrinsic mitochondrial pathway but through the non-mitochondrial production of ROS via the NADPH oxidase complex and endoplasmic reticulum system (32).
Our laboratory demonstrated that NPC cells proceeded to apoptosis following EBV lytic cycle induction by SAHA (12) . In this study, we critically investigated the expression kinetics of EBV lytic proteins (Zta, Rta, BMRF1 and gp350/220) and apoptotic markers (PARP and cleaved caspase-9) after treatment with either bortezomib or SAHA alone or bortezomib/SAHA in the NPC cells. We found that 
bortezomib/SAHA induced apoptosis of NPC cells at an earlier time point than either drug alone and bortezomib reduced SAHA's induction of EBV lytic cycle. Moreover, cleavage of caspase-9 and PARP was detected much earlier than the expression of EBV lytic proteins, indicating that bortezomib/SAHA potently and briskly induced cell death through apoptotic pathways independent of EBV lytic cycle activation.
Interestingly, this drug combination will also serve to minimize the production of this oncogenic virus from the NPC cells. The results were analyzed for statistical significance using unpaired student's t-test. P value < 0.05 was considered statistically significant; ***p < 0.001, **p < 0.01 and *p 
